C12N2506/45

AMNIOTIC-LIKE EPITHELIAL CELL GENERATION
20230235279 · 2023-07-27 ·

The present invention relates to a reliable method for producing amniotic-like epithelial cells, using a new methodology. The invention also relates to a composition and the use of said composition comprising amniotic-like epithelial cells or a preparation derived therefrom. Said cells may have particular utility in regenerative medicine, research and/or cosmetic preparations.

SERUM-FREE INDUCTION METHOD FOR SENSORY NEURON CELL
20230235282 · 2023-07-27 ·

Provided is a human-derived sensory neuron induction culture system. A combination of a small molecule inhibitor LY2157299 and a growth factor is added into a serum-free basal medium. Compared with an induction method involving serum, not only is the efficiency of inducing pluripotent stem cells into sensory neurons greatly improved, but the expression of a variety of ion channel proteins is also significantly improved, thereby achieving successful induction of multiple induced pluripotent stem cells from different sources into sensory neurons.

METHODS FOR PRODUCING OR ISOLATING EPICARDIAL CELLS AND USES THEREOF
20230002734 · 2023-01-05 ·

The invention relates to in vitro methods for isolating, or producing selected populations of human epicardial cells derived from human pluripotent stem cells; defined mixtures of said cells, and therapeutic uses thereof. Said population comprises epicardial cells with or without the potential to differentiate into cardiac fibroblasts, or a mixture thereof.

COMBINING IPSC DERIVED EFFECTOR CELL TYPES FOR IMMUNOTHERAPY USE
20230235287 · 2023-07-27 ·

Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors or additional cells in combination therapies.

HLA-F-MODIFIED CELLS AND METHODS
20230233610 · 2023-07-27 ·

The present disclosure provides compositions and methods for cell transplantation therapy based on forced expression of an exogenous HLA-F protein in donor cells to be transplanted into a subject. In some embodiments, the donor cells express an exogenous chimeric HLA-F protein comprising an extracellular region comprising an HLA-F alpha 1 domain, an HLA alpha 2 domain, an HLA-F alpha 3 domain, a linker and a β2m protein.

METHOD FOR FREEZING NEURAL CELLS

Provided is a method for freezing a cell aggregate including neural cells. provided is a method for freezing a cell aggregate including neural cells and having a three-dimensional structure, which comprises following steps (1) and (2): (1) contacting a cell aggregate including neural cells and having a three-dimensional structure with a preservation solution at 0° C. to 30° C. prior to freezing to prepare a preservation solution-soaked cell aggregate; and (2) cooling the preservation solution-soaked cell aggregate obtained in step (1) from a temperature at least about 5° C. higher than the freezing point of the preservation solution to a temperature about 5° C. lower than the freezing point at an average cooling speed of 2 to 7° C./min to freeze the cell aggregate.

THYMUS ORGANOIDS BIOENGINEERED FROM HUMAN PLURIPOTENT STEM CELLS
20230002727 · 2023-01-05 ·

This document relates to bioengineering and involves bioengineered thymus organoids and related humanized animal models. The thymus organoids and animal models have various commercial and clinical uses, including generating humanized antibodies, making antigen-specific human T cells, inducing transplantation tolerance, rejuvenating thymus functions, and modeling human diseases.

T-CELL MASTER CELL BANK

The present invention provides a system for providing a T cell product, including a T cell master cell bank and/or a T cell working cell bank.

COMPOSITIONS AND METHODS FOR GENERATION OF SINOATRIAL NODE-LIKE CELLS AND THEIR USE IN DRUG DISCOVERY
20230000924 · 2023-01-05 ·

Provided are methods for producing population of cells enriched for cells exhibiting sinoatrial node like characteristics. The cells can be produced from human pluripotent cells. Also provided are methods for using the SAN-like cells for identifying agents that can mitigate drug-induced cardiac toxicity. Also provided is a method for mitigating drug induced cardiotoxicity comprising administering to a subject an effective amount of physcion or a derivative thereof.

ENDODERM DIFFERENTIATION FROM PLURIPOTENT STEM CELL LINES
20230002736 · 2023-01-05 ·

Provided are methods for inducing differentiation of pluripotent stem cells, e.g., induced pluripotent stem cells, to form definitive endoderm. Also provided are methods for producing more committed endodermal cells such as hepatoblasts or hepatocytes.